Combinations of Topoisomerase Inhibitors and Ionizing Radiation

  • Michael Bastasch
  • Hak Choy
Part of the Medical Radiology book series (MEDRAD)


Clin Oncol Radiat Oncol Biol Phys Radiation Therapy Oncology Group Diffuse Intrinsic Pontine Glioma Elective Nodal Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ajani JA, Walsh G, Komaki R et al (2004) Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100:2347–2354PubMedCrossRefGoogle Scholar
  2. Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37:777–782PubMedCrossRefGoogle Scholar
  3. Amorino GP, Hercules SK, Mohr PJ et al (2000) Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer. Int J Radiat Oncol Biol Phys 47:503–509PubMedCrossRefGoogle Scholar
  4. Andoh T, Ishii K, Suzuki Y et al (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565–5569PubMedCrossRefGoogle Scholar
  5. Ang KK, Harris J, Garden AS et al (2005) Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncolo Gy group phase-II trial 99-14. J Clin Oncol 23:3008–3015PubMedCrossRefGoogle Scholar
  6. Araki E, Ishikawa M, Iigo M et al (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697–702PubMedGoogle Scholar
  7. Arriagada R, Pellae-Cosset B, Ladron de Guevara JC et al (1991) Alternating radiotherapy and chemotherapy schedules in limited small cell lung cancer: analysis of local chest recurrences. Radiother Oncol 20:91–98PubMedCrossRefGoogle Scholar
  8. Bae YS, Kawasaki I, Ikeda H et al (1988) Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA 85:2076–2080PubMedCrossRefGoogle Scholar
  9. Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27:843–850PubMedCrossRefGoogle Scholar
  10. Blaney SM, Phillips PC, Packer RJ et al (1996) Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78:527–531PubMedCrossRefGoogle Scholar
  11. Bonner JA, Kozelsky TF (1996) The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 39:109–112PubMedCrossRefGoogle Scholar
  12. Boothman DA, Wang M, Schea RA et al (1992) Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 24:939–948PubMedGoogle Scholar
  13. Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135PubMedCrossRefGoogle Scholar
  14. Chastagner P, Kozin SV, Taghian A (2001) Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. Int J Radiat Oncol Biol Phys 50:777–782PubMedCrossRefGoogle Scholar
  15. Chen AY, Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191–218PubMedCrossRefGoogle Scholar
  16. Chen AY, Okunieff P, Pommier Y et al (1997) Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529–1536PubMedGoogle Scholar
  17. Chen AY, Choy H, Rothenberg ML (1999) DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncolo Gy 13:39–46Google Scholar
  18. Cheng MF, Chatterjee S, Berger NA (1994) Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269–279PubMedGoogle Scholar
  19. Choy H, MacRae R (2001) Irinotecan and radiation in combined-modality therapy for solid tumors. Oncolo Gy 15:22–28Google Scholar
  20. Choi NC, Herndon JE 2nd, Rosenman J et al (1998) Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 16:3528–3536PubMedGoogle Scholar
  21. Ciesielski MJ, Fenstermaker R (1999) Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation. J Neurooncol 41:223–234PubMedCrossRefGoogle Scholar
  22. Ciusani E, Croci D, Gelati M et al (2005) In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J Neurooncol 71:19–25PubMedCrossRefGoogle Scholar
  23. Clamon G, Herndon J, Cooper R et al (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncolo Gy Group. J Clin Oncol 17:4–11PubMedGoogle Scholar
  24. Clark PI, Cottier B (1992) The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 19:36–39PubMedGoogle Scholar
  25. Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncolo Gy Group. J Am Med Assoc 281:1623–1627CrossRefGoogle Scholar
  26. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944PubMedCrossRefGoogle Scholar
  27. Curran WJ Jr, Scott C, Langer C et al (2000) Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncolo Gy Group (RTOG) 9410 (Abstract 1891). Lung Cancer 29:303aCrossRefGoogle Scholar
  28. Dombernowsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand [A] 81:715–724Google Scholar
  29. Downes CS, Mullinger AM, Johnson RT (1991) Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc Natl Acad Sci USA 88:8895–8899PubMedCrossRefGoogle Scholar
  30. Downes CS, Clarke DJ, Mullinger AM et al (1994) A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372:467–470PubMedCrossRefGoogle Scholar
  31. Einhorn LH, Pennington K, McClean J (1992) Phase-II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncolo Gy Group study. Semin Oncol 17:32–35Google Scholar
  32. Escargueil AE, Plisov SY, Skladanowski A et al (2001) Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J 15:2288–2290PubMedGoogle Scholar
  33. Fisher BJ, Scott C, Macdonald DR et al (2001) Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncolo Gy Group Trial 9507. J Clin Oncol 19:1111–1117PubMedGoogle Scholar
  34. Fisher B, Won M, Macdonald D et al (2002) Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncolo Gy Group 9513. Int J Radiat Oncol Biol Phys 53:980–986PubMedCrossRefGoogle Scholar
  35. Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396–2402PubMedGoogle Scholar
  36. Fu KK, Cooper JS, Marcial VA et al (1996) Evolution of the Radiation Therapy Oncolo Gy Group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 35:425–438PubMedCrossRefGoogle Scholar
  37. Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncolo Gy Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16PubMedCrossRefGoogle Scholar
  38. Giocanti N, Hennequin C, Balosso J et al (1993) DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53:2105–2111PubMedGoogle Scholar
  39. Grabenbauer GG, Anders K, Fietkau RJ et al (2002) Prolonged infusional topotecan and accelerated hyperfractionated 3D-conformal radiation in patients with newly diagnosed glioblastoma: a phase I study. J Neurooncol 60:269–275PubMedCrossRefGoogle Scholar
  40. Graham MV, Jahanzeb M, Dresler CM et al (1996) Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 36:1215–1220PubMedCrossRefGoogle Scholar
  41. Gross MW, Altscher R, Brandtner M et al (2001) Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin). Strahlenther Onkol 177:656–661PubMedCrossRefGoogle Scholar
  42. Haddock MG, Ames MM, Bonner JA (1995) Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70:1053–1060PubMedCrossRefGoogle Scholar
  43. Hainsworth JD, Johnson DH, Frazier SR et al (1990) Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 26:818–821PubMedCrossRefGoogle Scholar
  44. Hammond LA, Eckardt JR, Ganapathi R et al (1998) A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res 4:1459–1467PubMedGoogle Scholar
  45. Han JY, Cho KH, Lee DH et al (2005) Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 23:3488–3494PubMedCrossRefGoogle Scholar
  46. Heck MM, Earnshaw WC (1986) Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103:2569–2581PubMedCrossRefGoogle Scholar
  47. Herskovic A, Martz K, al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598PubMedGoogle Scholar
  48. Hofheinz RD, Gerstenberg-Helldorf B von, Wenz F et al (2005) Phase-I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350–1357PubMedCrossRefGoogle Scholar
  49. Humerickhouse RA, Stenson K, Brockstein B et al (2000) Phase I study of irinotecan (CPT-11), 5-FU, and hydroxyurea with radiation in recurrent or advanced head and neck cancer (Abstract). Proc Am Soc Clin Oncol 19:418aGoogle Scholar
  50. Ilson DH, Saltz L, Enzinger P et al (1999) Phase-II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270–3275PubMedGoogle Scholar
  51. Ilson DH, Bains M, Kelsen DP et al (2003) Phase-I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21:2926–2932PubMedCrossRefGoogle Scholar
  52. Iwata T, Kanematsu T (1999) Etoposide enhances the lethal effect of radiation on breast cancer cells with less damage to mammary gland cells. Cancer Chemother Pharmacol 43:284–286PubMedCrossRefGoogle Scholar
  53. Jacobs C, Lyman G, Velez-Garcia E et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257–263PubMedGoogle Scholar
  54. Janss AJ, Cnaan A, Zhao H et al (1998) Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs 9:641–652PubMedGoogle Scholar
  55. Johnson FM, Kurie JM, Peeples BO et al (2003) Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5:40–45PubMedCrossRefGoogle Scholar
  56. Kalwinsky DK, Look AT, Ducore J et al (1983) Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43:1592–1597PubMedGoogle Scholar
  57. Kaneko M, Horikoshi J (1987) Topoisomerase inhibitors suppressed lithocholic acid-induced promotion of transformation in BALB/3T3. Br J Cancer 56:614–616PubMedGoogle Scholar
  58. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129–1136PubMedGoogle Scholar
  59. Kawato Y, Aonuma M, Hirota Y et al (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191PubMedGoogle Scholar
  60. Kim JH, Kim SH, Kolozsvary A et al (1992) Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 22:515–518PubMedGoogle Scholar
  61. Kim JS, Amorino GP, Pyo H et al (2002) Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol 62:61–67PubMedCrossRefGoogle Scholar
  62. Kirichenko AV, Rich TA, Newman RA et al (1997) Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer Res 57:1929–1933PubMedGoogle Scholar
  63. Kohara H, Tabata M, Kiura K et al (2002) Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res 8:287–292PubMedGoogle Scholar
  64. Komaki R, Janjan NA, Ajani JA et al (2000) Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncolo Gy 14:34–37Google Scholar
  65. Komaki R, Swann RS, Ettinger DS et al (2005) Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncolo Gy Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62:342–350PubMedCrossRefGoogle Scholar
  66. Koukourakis MI, Bizakis JG, Skoulakis CE et al (1999) Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 19:2305–2309Google Scholar
  67. Kubota K, Nishiwaki Y, Sugiura T et al (2005) Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncolo Gy Group 9903. Clin Cancer Res 11:5534–5538PubMedCrossRefGoogle Scholar
  68. Lamond JP, Wang M, Kinsela TJ, Boothman DA (1996) Radiation lethalityenhancement with 9 aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys 36:369–376PubMedCrossRefGoogle Scholar
  69. Larsen AK, Escargueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99:167–181PubMedCrossRefGoogle Scholar
  70. Macdonald D, Cairncross G, Stewart D et al (1996) Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7:205–207Google Scholar
  71. Maksymiuk AW, Jett JR, Earle JD et al (1994) Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 12:70–76PubMedGoogle Scholar
  72. Marples B, Adomat H, Koch CJ et al (1996) Response of V79 cells to low doses of X-rays and negative pi-mesons: clonogenic survival and DNA strand breaks. Int J Radiat Biol 70:429–436PubMedCrossRefGoogle Scholar
  73. Mehta VK, Cho C, Ford JM et al (2003) Phase-II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132–137PubMedCrossRefGoogle Scholar
  74. Muggia FM, Creaven PJ, Hansen HH et al (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515–521PubMedGoogle Scholar
  75. Murphy BA, Cmelak A, Burkey B et al (2001) Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncolo Gy 15:47–52Google Scholar
  76. Murray N, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336–344PubMedGoogle Scholar
  77. Ng CE, Bussey AM, Raaphorst GP (1994) Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. Int J Radiat Biol 66:49–57PubMedGoogle Scholar
  78. Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91PubMedCrossRefGoogle Scholar
  79. Pommier Y, Schwartz RE, Kohn KW et al (1984) Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 23:3194–3201PubMedCrossRefGoogle Scholar
  80. Pommier Y, Pourquier P, Fan Y et al (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83–105PubMedGoogle Scholar
  81. Sakamoto S, Nishikawa K, Heo SJ et al (2001) Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51. Genes Cells 6:421–430PubMedCrossRefGoogle Scholar
  82. Salama JK, Vokes EE, Chmura SJ et al (2005) Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, epubGoogle Scholar
  83. Sanghavi SN, Needle MN, Krailo MD et al (2003) A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro-oncolo Gy 5:8–13CrossRefGoogle Scholar
  84. Scagliotti GV, Ricardi U, Crino L et al (1996) Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colonystimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. Cancer Chemother Pharmacol 38:561–565PubMedCrossRefGoogle Scholar
  85. Sekine I, Nishiwaki Y, Noda K et al (2003) Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive smallcell lung cancer (JCOG9902-DI). Ann Oncol 14:709–714PubMedCrossRefGoogle Scholar
  86. Sierocki JS, Hilaris BS, Hopfan S et al (1979) cis-Dichlorod iammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593–1597PubMedGoogle Scholar
  87. Socinski MA, Morris DE, Halle JS et al (2004) Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase-I trial. J Clin Oncol 22:4341–4350PubMedCrossRefGoogle Scholar
  88. Takada M, Fukuoka M, Kawahara M et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncolo Gy Group Study 9104. J Clin Oncol 20:3054–3060PubMedCrossRefGoogle Scholar
  89. Takahashi T, Mitsuhashi N, Akimoto T et al (2003) Interaction of radiation and etoposide on two cell lines with different radiosensitivities in vitro. Anticancer Res 23:3459–3464PubMedGoogle Scholar
  90. Takeda K, Negoro S, Takifuji N et al (2001) Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48:104–108PubMedCrossRefGoogle Scholar
  91. Takimoto CH, Wright J, Arbuck SG (1998) Clinical applications of the camptothecins. Biochim Biophys Acta 1400:107–119PubMedGoogle Scholar
  92. Turner CD, Gururangan S, Eastwood J et al (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neurooncolo Gy 4:102–108Google Scholar
  93. Turrisi AT, Glover DJ, Mason BA (1988) Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for the treatment of limited small cell lung cancer: a preliminary report. Antibiot Chemother 41:109–114PubMedGoogle Scholar
  94. Turrisi AT, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271PubMedCrossRefGoogle Scholar
  95. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54:665–697PubMedCrossRefGoogle Scholar
  96. Wang JC (1991) DNA topoisomerases: why so many? J Biol Chem 266:6659–6662PubMedGoogle Scholar
  97. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440PubMedCrossRefGoogle Scholar
  98. Wang Z, Sinha BK (1996) Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of syner Gy with camptothecins in vitro and in vivo. Mol Pharmacol 49:269–275PubMedGoogle Scholar
  99. Whitacre CM, Zborowska E, Gordon NH et al (1997) Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57:1425–1428PubMedGoogle Scholar
  100. Yamada M, Kudoh S, Fukuda H et al (2002) Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer 87:258–263PubMedCrossRefGoogle Scholar
  101. Yokoyama A, Kurita Y, Saijo N et al (1998) Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer 78:257–262PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Michael Bastasch
    • 1
  • Hak Choy
    • 1
  1. 1.Department of Radiation OncologyThe University of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations